Dawn Harbatkin, MD
Addiction Medicine · Amherst, NYNPI 1033119284
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Indivior Inc. at 52.4% of the total. Reporting peaked in 2024 at $5,052 and has fallen 83.2% since, to $847 in 2025.
Across 149 payments — averaging $43.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$3K
- Supernus Pharmaceuticals, Inc.$491
- Teva Pharmaceuticals USA, Inc.$379
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$274
- Idorsia Pharmaceuticals US Inc$247
- Lundbeck LLC$207
- plus $1K from 23 others
Across 319 payments — averaging $328.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$105K
What the payments were for
- Consulting fees$1,93830%
- Travel & lodging$1,09017%
- Food & beverage$3,41253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 12 | $3,374 |
| Supernus Pharmaceuticals, Inc. | 2 | $491 |
| Teva Pharmaceuticals USA, Inc. | 27 | $379 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $274 |
| Idorsia Pharmaceuticals US Inc | 13 | $247 |
| Lundbeck LLC | 13 | $207 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $153 |
| Alkermes, Inc. | 6 | $122 |
| Vanda Pharmaceuticals Inc. | 6 | $120 |
| Braeburn Inc. | 3 | $117 |
| Axsome Therapeutics, Inc. | 5 | $111 |
| Neurocrine Biosciences, Inc. | 5 | $109 |
| Johnson & Johnson | 5 | $96 |
| AstraZeneca(2 entities) | 5 | $95 |
| Grifols USA, LLC | 2 | $67 |
| Averitas Pharma Inc. | 2 | $34 |
| Noven Therapeutics, LLC | 2 | $34 |
| EMD Serono, Inc. | 1 | $33 |
| Corium, LLC | 1 | $27 |
| ITF Therapeutics LLC | 1 | $26 |
| Eisai Inc. | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $21 |
| Biogen | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$472
How this compares
$6,440 in reported general payments places this provider in the 85th percentile of 125 addiction medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SublocadeBuprenorphine | 29 | $57,760 |
| VivitrolNaltrexone Microspheres | 13 | $21,302 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 145 | $17,580 |
| Varenicline Tartrate | 45 | $9,646 |
| Acamprosate Calcium | 42 | $6,309 |
| Naltrexone Hcl | 43 | $2,619 |
| Bupropion XlBupropion Hcl | 65 | $945 |
| Gabapentin | 20 | $145 |
| Diazepam | 30 | $142 |
| Topiramate | 31 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Sublocade | $3,374 | $57,76029 claims |
| Alkermes, Inc.Vivitrol | $122 | $21,30213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 125 addiction medicine providers in New York.
Other addiction medicine in Amherst
- Edmond HakimiCalverton$125K
- Alain LitwinBronx$124K
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Alejo ParelladaBrooklyn$22K
- Sean ChappinAlbany$20K
- Mohammad KabirTroy$15K
- Sonia LopezJamaica$14K
- Thomas KuettelWorcester$14K
- Ramon RaveloNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.